AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30382002 — intervention group
Group type: COMPARATOR
Intervention: Standard care with placebo
Number of subjects: 388
Study 30382002 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictors during inpatient therapeutic care (ITC)
Number of subjects: 388
Study 30382002 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictors during outpatient therapeutic care (OTC)
Number of subjects: 388
Study 28931089 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month dietary AGE restriction (LAGE, n = 10)
Number of subjects: 20
Study 28931089 — intervention group
Group type: COMPARATOR
Intervention: Continuing the same diet (HAGE, n = 10)
Number of subjects: 20
Study 26138203 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg sprifermin
Number of subjects: 168
Study 26138203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 23638956 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (curettage)
Number of subjects: 0
Study 23638956 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study 21854617 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip op Je Dip (GOJD) online group course
Number of subjects: 244
Study 21854617 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 244
Study 19636360 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist (levodopa)
Number of subjects: 0
Study 19636360 — intervention group
Group type: COMPARATOR
Intervention: Dopamine antagonist (haloperidol)
Number of subjects: 0
Study 19636360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 19636360 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anticipated reward
Number of subjects: 0
Study 17062039 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% foam (CF)
Number of subjects: 34
Study 17062039 — intervention group
Group type: COMPARATOR
Intervention: Placebo foam (PF)
Number of subjects: 34
Study 15105978 — intervention group
Group type: EXPERIMENTAL
Intervention: Multislice CT (CTA)
Number of subjects: 50
Study 15105978 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography (DSA)
Number of subjects: 50
Study 11726616 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium oxygen‐permeable (Dk) RGP lenses
Number of subjects: 200
Study 11726616 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen‐permeable (Dk) RGP lenses
Number of subjects: 200
Study 11726616 — intervention group
Group type: COMPARATOR
Intervention: Both medium and high oxygen‐permeable (Dk) RGP lenses
Number of subjects: 200
Study 9141982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal steroid (fluticasone) 200 micrograms when needed (up to 400 micrograms/d) + 1-2 tablets of terfenadine daily (max 120 mg/d)
Number of subjects: 61
Study 9141982 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine (terfenadine) 1 tablet of 60 mg when needed (max 120 mg/d) + 200-400 micrograms/d of fluticasone nasal spray if needed
Number of subjects: 61
Study 7968554 — intervention group
Group type: EXPERIMENTAL
Intervention: New context during testing
Number of subjects: 0
Study 7968554 — intervention group
Group type: COMPARATOR
Intervention: Different context experienced during learning
Number of subjects: 0
Study 3099611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium nasal spray for 6 weeks together with terfenadine for 1 week
Number of subjects: 0
Study 3099611 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine alone for 6 weeks
Number of subjects: 0
Study 31141465 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 84
Study 31141465 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 84
Study 30203772 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 0
Study 30203772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 0
Study 30203772 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 0
Study 30203772 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 28592016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (30‐75 mg, twice daily for 5 days)
Number of subjects: 229
Study 28592016 — intervention group
Group type: COMPARATOR
Intervention: Control (symptom relief medicines for 5 days)
Number of subjects: 229
Study 28592016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (in patients confirmed with positive virus test)
Number of subjects: 229
Study 28592016 — intervention group
Group type: COMPARATOR
Intervention: Control (in patients confirmed with positive virus test)
Number of subjects: 229
Study 28592016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (in patients who completed the course)
Number of subjects: 229
Study 28592016 — intervention group
Group type: COMPARATOR
Intervention: Control (in patients who completed the course)
Number of subjects: 229
Study 25903940 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg
Number of subjects: 12
Study 25903940 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 150 mg
Number of subjects: 12
Study 25903940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23916633 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 81
Study 23916633 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 81
Study 20835580 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion with 37% phosphoric acid (group I)
Number of subjects: 40
Study 20835580 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion with self-priming etchant (Tyrian-SPE) (group II)
Number of subjects: 40
Study 20835580 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbine with 37% phosphoric acid (group III)
Number of subjects: 40
Study 20835580 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbine with self-priming etchant (Tyrian-SPE) (group IV)
Number of subjects: 40
Study 18182196 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion pump with 0.5% bupivacaine
Number of subjects: 76
Study 18182196 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene regional block
Number of subjects: 76
Study 18182196 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block combined with an infusion pump containing 0.9% saline solution
Number of subjects: 76
Study 18182196 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block combined with an infusion pump containing 0.5% bupivacaine
Number of subjects: 76
Study 18182196 — intervention group
Group type: COMPARATOR
Intervention: Control group (Infusion pump with saline solution)
Number of subjects: 76
Study 15906076 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LI 4 and PC 6 points for 15 min (Group A)
Number of subjects: 29
Study 15906076 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LI 4 and PC 6 points for 15 min (Group C)
Number of subjects: 29
Study 15906076 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) - acupuncture needles inserted subcutaneously
Number of subjects: 29
Study 12774013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mIU IFN‐alpha2b daily for 1 month followed by 3 mIU IFN‐alpha2b 3 times a week with ribavirin
Number of subjects: 35
Study 10589439 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata dried extract (1200 mg/day)
Number of subjects: 158
Study 10589439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 8636343 — intervention group
Group type: COMPARATOR
Intervention: Fludrocortisone 0 mg (placebo)
Number of subjects: 14
Study 8636343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.1 mg
Number of subjects: 14
Study 8636343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.2 mg
Number of subjects: 14
Study 2019178 — intervention group
Group type: COMPARATOR
Intervention: Monosodium glutamate (MSG), 9 g, intravenous loading
Number of subjects: 6
Study 2019178 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG)
Number of subjects: 6
Study 6168840 — intervention group
Group type: COMPARATOR
Intervention: Pindolol (10‐45 mg/day)
Number of subjects: 16
Study 31033396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad exposure frequency (viewing the ad once, twice, or four times)
Number of subjects: 616
Study 28324627 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine induction and dose stabilization during hospitalization followed by post-discharge transition to office-based buprenorphine treatment (OBOT)
Number of subjects: 72
Study 25872502 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypercapnia (PaCO2 50 to 55 mmHg)
Number of subjects: 0
Study 25872502 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (PaCO2 35 to 45 mmHg)
Number of subjects: 0
Study 23009254 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-patients PBL (RPBL)
Number of subjects: 120
Study 23009254 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital PBL (DPBL)
Number of subjects: 120
Study 23009254 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper PBL (PPBL)
Number of subjects: 120
Study 23009254 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 120
Study 21826009 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVIGLOB/sdNVP
Number of subjects: 492
Study 21826009 — intervention group
Group type: COMPARATOR
Intervention: sdNVP
Number of subjects: 492
Study 19180894 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied to one-half of the face, 2-times-per-week for 16 weeks after photodynamic therapy.
Number of subjects: 25
Study 19180894 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied to the other half of the face, 2-times-per-week for 16 weeks after photodynamic therapy.
Number of subjects: 25
Study 17728605 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase bone scintigraphy (TPBS) - vascular phase
Number of subjects: 26
Study 17728605 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase bone scintigraphy (TPBS) - blood pool phase
Number of subjects: 26
Study 17728605 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase bone scintigraphy (TPBS) - delayed phase
Number of subjects: 26
Study 17728605 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase bone scintigraphy (TPBS) - any phase positive finding
Number of subjects: 26
Study 17728605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CRPS)
Number of subjects: 26
Study 13680283 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x2 mg budesonide
Number of subjects: 104
Study 13680283 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x3 mg budesonide
Number of subjects: 104
Study 13680283 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x6 mg budesonide
Number of subjects: 104
Study 11679989 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 1 x 10(6) KIU/h, and 1 x 10(6) KIU before reperfusion; n = 10)
Number of subjects: 27
Study 11679989 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin (2 x 10(6) KIU at induction and continuous infusion of 0.5 x 10(6) KIU/h; n = 8)
Number of subjects: 27
Study 11679989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 27
Study 9461726 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 0
Study 8003847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (n = 939)
Number of subjects: 3222
Study 8003847 — intervention group
Group type: COMPARATOR
Intervention: Non-users (n = 2283)
Number of subjects: 3222
Study 8003847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (n = 939) among women who had never used oestrogen replacement therapy (n = 1427)
Number of subjects: 3222
Study 8003847 — intervention group
Group type: COMPARATOR
Intervention: Non-users (n = 2283) among women who had never used oestrogen replacement therapy (n = 1427)
Number of subjects: 3222
Study 8003847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (n = 939) among premenopausal women (n = 387)
Number of subjects: 3222
Study 8003847 — intervention group
Group type: COMPARATOR
Intervention: Non-users (n = 2283) among premenopausal women (n = 387)
Number of subjects: 3222
Study 3341390 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1 mg per day
Number of subjects: 15
Study 3341390 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg per day
Number of subjects: 15
Study 3341390 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 5.0 mg per day
Number of subjects: 15
Study 3341390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29799999 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Bone Scan Index (aBSI)
Number of subjects: 1245
Study 27507634 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care supplemented by a pain consultation combined with a patient pain education program
Number of subjects: 72
Study 27507634 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 72
Study 26514499 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC home nursing plan
Number of subjects: 180
Study 24133104 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF physiotherapy
Number of subjects: 34
Study 24133104 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 34
Study 21138901 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐(+)‐ketamine
Number of subjects: 128
Study 21138901 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 128
Study 18197915 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Number of subjects: 41
Study 18197915 — intervention group
Group type: COMPARATOR
Intervention: Fixed-CPAP
Number of subjects: 41
Study 18197915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 41
Study 17184605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei and Streptococcus thermophilus (0.5 l/day) for 6 weeks
Number of subjects: 35
Study 17184605 — intervention group
Group type: COMPARATOR
Intervention: Standard cow's milk (0.5 l/day) for 12 weeks
Number of subjects: 35
Study 15004973 — intervention group
Group type: EXPERIMENTAL
Intervention: Zi-Factor (250 mg azithromycin capsules)
Number of subjects: 18
Study 15004973 — intervention group
Group type: COMPARATOR
Intervention: Reference-drug
Number of subjects: 18
Study 10974397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pluronic F-68 with nifedipine
Number of subjects: 12
Study 10974397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine with fixed ratio of 1.5 (inner to outer layer)
Number of subjects: 12
Study 10974397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine with a 1:1 ratio of inner to outer layer
Number of subjects: 12
Study 10974397 — intervention group
Group type: COMPARATOR
Intervention: Cardilate (test product)
Number of subjects: 12
Study 8979392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference condition (activation of significant-other representation)
Number of subjects: 0
Study 8979392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference condition
Number of subjects: 0
Study 1435883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Number of subjects: 252
Study 1435883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 6377153 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-g oral dose of metronidazole (Flagyl)
Number of subjects: 42
Study 6377153 — intervention group
Group type: COMPARATOR
Intervention: Seven-day regimen of metronidazole
Number of subjects: 42
Study 31518339 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (Group 1)
Number of subjects: 0
Study 31518339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Charge HR (Group 2)
Number of subjects: 0
Study 31518339 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Charge HR and office visits (Group 3)
Number of subjects: 0
Study 28383398 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product containing Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052
Number of subjects: 200
Study 28383398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 28383398 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product
Number of subjects: 200
Study 25769076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 98
Study 25769076 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 98
Study 23405164 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Age (brain training game)
Number of subjects: 32
Study 23405164 — intervention group
Group type: COMPARATOR
Intervention: Tetris (puzzle game)
Number of subjects: 32
Study 21269980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime injection of glargine and oral antidiabetic drugs (group A)
Number of subjects: 0
Study 21269980 — intervention group
Group type: COMPARATOR
Intervention: Injection of Novolin 30 R twice a day (group B)
Number of subjects: 0
Study 19091420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 4577
Study 18693603 — intervention group
Group type: EXPERIMENTAL
Intervention: True Positive ETT
Number of subjects: 148
Study 18693603 — intervention group
Group type: COMPARATOR
Intervention: False Positive ETT
Number of subjects: 148
Study 14707416 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS)
Number of subjects: 39
Study 11257348 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib combination vaccine
Number of subjects: 0
Study 11257348 — intervention group
Group type: COMPARATOR
Intervention: Separate Hib conjugates
Number of subjects: 0
Study 9493717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal asthma (NA) group
Number of subjects: 45
Study 9493717 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nocturnal asthma (NNA) group
Number of subjects: 45
Study 9493717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 9493717 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 8116704 — intervention group
Group type: COMPARATOR
Intervention: Video colposcope viewing (study 1)
Number of subjects: 57
Study 8116704 — intervention group
Group type: COMPARATOR
Intervention: Music video viewing (study 2)
Number of subjects: 57
Study 3415794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap automated oscillometric blood pressure monitor
Number of subjects: 42
Study 31876907 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) after PCI
Number of subjects: 15991
Study 31876907 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin monotherapy
Number of subjects: 15991
Study 31876907 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (ticagrelor)
Number of subjects: 15991
Study 31876907 — intervention group
Group type: COMPARATOR
Intervention: Reference arm (DAPT followed by aspirin)
Number of subjects: 15991
Study 31876907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 15991
Study 31539276 — intervention group
Group type: EXPERIMENTAL
Intervention: Five differentially expressed long noncoding RNAs (LINC00475, LINC01352, MIR503HG, KCNMB2‐AS1, LINC01143) used to establish a risk score model.
Number of subjects: 526
Study 31539276 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model based on five DELs.
Number of subjects: 526
Study 31539276 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model.
Number of subjects: 526
Study 31539276 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score in nomogram model.
Number of subjects: 526
Study 31539276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanism analyses of lncRNAs.
Number of subjects: 526
Study 28250181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 28250181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26390102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-Augmented Pump (SAP)
Number of subjects: 60
Study 26390102 — intervention group
Group type: COMPARATOR
Intervention: Multiple Daily Injections (MDI)
Number of subjects: 60
Study 23735264 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance letter
Number of subjects: 1000
Study 23735264 — intervention group
Group type: COMPARATOR
Intervention: No advance letter
Number of subjects: 1000
Study 21687920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidisciplinary programme (NMP) of pulmonary rehabilitation
Number of subjects: 103
Study 21687920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 103
Study 18611978 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E(2) supplementation
Number of subjects: 20
Study 18611978 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 20
Study 16488678 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration 4 hours postoperatively, daily for 4 weeks
Number of subjects: 364
Study 16488678 — intervention group
Group type: COMPARATOR
Intervention: No clopidogrel administration
Number of subjects: 364
Study 16488678 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration
Number of subjects: 364
Study 12560924 — intervention group
Group type: EXPERIMENTAL
Intervention: LSTs
Number of subjects: 65
Study 12560924 — intervention group
Group type: COMPARATOR
Intervention: Exophytic tumors
Number of subjects: 65
Study 11023194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral interferon-gamma (IFN-gamma) retroviral vector, 10(7) plaque-forming units/mL administered at 0.3, 0.5, and 1.0 mL per cohort of patients, five daily injections every 2 weeks.
Number of subjects: 17